Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder
- 39 Downloads
There is not yet a standardized approach to treat patients with small cell carcinoma of the bladder (SmCCB). This study aims to investigate the clinical features, treatment, and survival outcomes of patients with pure SmCCB.
Materials and methods
Patients diagnosed with SmCCB between January 2006 and September 2015 were retrospectively evaluated.
A total of 34 patients with a median age of 63.0 years were included in the study, with a male to female ratio of 4.6:1.0. At the time of diagnosis, 22 patients (64.7%) had stage IV disease. At a median follow-up time of 12.7 months, 67.6% of patients died of bladder carcinoma, with an overall survival (OS) of 15.7 months for all patients. In the patients with stages I–III, nodal involvement, and distant metastases, the median OS was 31.8, 15.7, and 8.4 months, respectively (P = 0.005). Considering the survival rates of the patients (stages I–III) treated with surgery vs. local therapy, there was not a statistically significant difference (26.6 months and 31.8 months, P = 0.97, respectively). A multivariate analysis revealed that stage IV disease and poor ECOG performance status were associated with OS.
The optimal treatment of SmCCB has been under debate. For the patients with advanced stage of disease (T4b, N+, M+), platinum containing chemotherapeutic agents should be preferred. Stage IV disease and poor ECOG performance status were associated with shorter OS.
KeywordsBladder Chemotherapy Neuroendocrine carcinoma Small cell carcinoma Surgery
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
No prospective studies with human participants or animals were performed by any of the authors for this article. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 4.Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN (2004) Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 101(5):957–962. https://doi.org/10.1002/cncr.20456 CrossRefPubMedGoogle Scholar
- 7.Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL (2010) AJCC Cancer staging manual, 7th edn, pp 497–502Google Scholar
- 8.Ismaili N, Heudel PE, Elkarak F, Kaikani W, Bajard A, Ismaili M, Errihani H, Droz JP, Flechon A (2009) Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol 9(4). https://doi.org/10.1186/1471-2490-9-4.
- 9.Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, Boujelbene N, Ghadjar P, Lassen-Ramshad Y, Senkus E, Oar A, Roelandts M, Amichetti M, Vees H, Zilli T, Ozsahin M (2015) Small cell carcinoma of the urinary bladder: a retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys 92(4):904–910. https://doi.org/10.1016/j.ijrobp.2015.03.019 CrossRefPubMedGoogle Scholar
- 10.Chen Z, Liu Q, Chen R, Liu Z, Li M, Ling Q, Wu L, Yang J, Liu X, Wang T, Hu Z, Guo X, Wang S, Yang W, Liu J (2017) Clinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature reviews. World J Surg Oncol 15(1):33. https://doi.org/10.1186/s12957-016-1079-y. CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J (2014) Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors 6(1):5043–5014. https://doi.org/10.4081/rt.2014.5043 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, Schwartz D (2013) Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol 36(2):126–131. https://doi.org/10.1097/COC.0b013e3182438c71 CrossRefPubMedGoogle Scholar
- 20.Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, Tarrell RF, Thompson RH (2015) Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol 22(6):549–554. https://doi.org/10.1111/iju.12729 CrossRefPubMedGoogle Scholar
- 23.Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE (2009) Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592–2597. https://doi.org/10.1200/JCO.2008.19.0256 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A (2013) Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 64(2):307–313. https://doi.org/10.1016/j.eururo.2012.04.020 CrossRefPubMedGoogle Scholar